EUVIMEDEUVIMED entdecken
Crossref

B Cells Undergo Transcriptional Changes Following Autoimmune Sicca Development in Melanoma Patients Treated with Immune Checkpoint Inhibitors 2256997

Hannah Bhattacharya, Rachel Bonami, Douglas Johnson, Tommi Taylor

The Journal of Immunology · 01.08.2026 · 215 (Supplement_1)

DOI: 10.1093/jimmun/vkag141.382 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.07.2026. Verfasst von Hannah Bhattacharya und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of melanoma and other cancers but can cause immune-related adverse events (irAEs) and lasting autoimmune tissue damage. One such irAE (ICI-sicca) shares some features with the rheumatic disease, Sjögren’s syndrome, with dry mouth being the symptom typically reported by ICI-sicca patients. A fraction of ICI-sicca patients have Sjögren’s-associated autoantibodies, signifying autoreactive B cell activity in this disease.

Methods

To identify B cell gene dysregulation that arises with ICI-sicca onset, we used single-cell RNA-sequencing to compare CD19+ cells isolated from peripheral blood collected 3-4 weeks after ICI therapy initiation (pre-ICI sicca) or following ICI-sicca symptom onset (post-ICI sicca) in n = 6 melanoma patients. Transcriptome-based clustering using Seurat identified n = 14 clusters, which we manually collapsed into five major B cell subsets (transitional, naïve, activated, memory, and plasmablasts).

Results

We observed upregulation of genes following ICI-sicca development in naïve (n = 1296 genes), activated (n = 42 genes), and memory (n = 775 genes) B cell subsets, relative to the pre-ICI sicca timepoint, based on adjusted p-value < 0.05 and fold change > 1.2 cutoffs. These upregulated genes were related to BCR signaling, actin cytoskeleton rearrangement, antigen processing and presentation, and interferon responses.

Conclusion

Some of the ICI-sicca upregulated genes were also noted to be increased in rheumatic disease patients relative to healthy controls in other single-cell RNA-seq studies performed by our lab, suggesting the potential for shared B cell liability across spontaneous and ICI-induced autoimmunity. Future studies will validate alteration of these key B cell functions and explore pharmacologic methods to restore this aberrant B cell rewiring as a means to generate new hypotheses that can be tested with the ultimate goal of limiting ICI sicca, and potentially other irAE development. Funding Source National Institutes of Health Grants R03 AI163835 (RHB), Luke and Susan Simons Directorship (DBJ), and K12 HD043483 (RHB), as well as the Vanderbilt University Summer Research Program (HB), MARC/START (HB) supported this work. Studies were performed using Topic Categories Tumor Immunology: Checkpoints, Prevention, and Treatment (TIPT)

Zitieren

APA

Bhattacharya, H., Bonami, R., Johnson, D., & Taylor, T. (2026). B Cells Undergo Transcriptional Changes Following Autoimmune Sicca Development in Melanoma Patients Treated with Immune Checkpoint Inhibitors 2256997. The Journal of Immunology, 215(Supplement_1). https://doi.org/10.1093/jimmun/vkag141.382

Vancouver

Bhattacharya H, Bonami R, Johnson D, Taylor T. B Cells Undergo Transcriptional Changes Following Autoimmune Sicca Development in Melanoma Patients Treated with Immune Checkpoint Inhibitors 2256997. The Journal of Immunology. 2026;215(Supplement_1). doi:10.1093/jimmun/vkag141.382

BibTeX
@article{Bhattacharya2026,
  author = {Bhattacharya, Hannah and Bonami, Rachel and Johnson, Douglas and Taylor, Tommi},
  title = {B Cells Undergo Transcriptional Changes Following Autoimmune Sicca Development in Melanoma Patients Treated with Immune Checkpoint Inhibitors 2256997},
  journal = {The Journal of Immunology},
  year = {2026},
  volume = {215},
  number = {Supplement_1},
  doi = {10.1093/jimmun/vkag141.382}
}
Kostenlos starten →